-

Ultivue to Participate in Cowen’s 41st Annual Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ultivue, an industry leader in multiplexing for tissue biomarker analysis, will participate in Cowen’s 41st Annual Health Care Conference, a virtual event taking place March 1-4, 2021. The conference incorporates presentations, fireside chats, and innovative panel discussions hosted by members of the Cowen research team that focus on various aspects of the health care industry.

Ultivue’s President and Chief Executive Officer, Jacques Corriveau, will host a series fireside chats, designed as one-on-one meetings with interested investors, on Tuesday, March 2nd.

About Ultivue

Ultivue provides researchers in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com.

About Cowen

Cowen Inc. (“Cowen” or the “Company”) is a diversified financial services firm offering investment banking services, equity and credit research, sales and trading, prime brokerage, global clearing, commission management services and actively managed alternative investment products. Cowen focuses on delivering value-added capabilities to our clients in order to help them outperform. Founded in 1918, the Company is headquartered in New York and has offices worldwide. Learn more at Cowen.com.

Contacts

Christopher Hynes
Ultivue
christopher.hynes@ultivue.com

Industry:

Ultivue

Release Versions
English

Contacts

Christopher Hynes
Ultivue
christopher.hynes@ultivue.com

Social Media Profiles
Ultivue
More News From Ultivue

Ultivue and ngTMA® Announce Collaborative Agreement to Provide Multiplex and Spatial Analysis for Clinical Research

CAMBRIDGE, Mass. & BERN, Switzerland--(BUSINESS WIRE)--Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies and, the Translational Research Unit (TRU) platform of University of Bern, that develops novel workflows for tissue microarray (ngTMA®) construction, announce a collaborative agreement to promote multiplexed immunofluorescence (mIF) assays and the use of next generation TMAs to unlock spatial analysis in scientific research...

Ultivue Announces AI Partner Ecosystem to Accelerate Analysis of Multiplex Immunofluorescence Image Data in Translational Medicine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ultivue, Inc., an industry leader in multiplexing assays and analytics solutions for tissue biomarker studies, announced today multiple collaborations for AI-powered spatial phenomics solutions for translational research groups and Biopharma. Ultivue develops unique workflows for use in both multiplex immunofluorescence (mIF) imaging and spatial phenomics. Its proprietary InSituPlex® technology is designed for fast and comprehensive exploration of biologically...

Ultivue Announces Co-Marketing and Co-Development Collaboration with Paige for AI-Powered Biomarker Imaging Solutions for Precision Medicine

CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ultivue, an industry leader in multiplexing tools for tissue biomarker analysis, and Paige, the global leader in AI-based diagnostic software in pathology, today announced a partnership to collaborate on the co-development and co-marketing of AI-powered spatial immunophenotype capabilities to pharmaceutical and research customers. Collaborative efforts will initially focus on the development of AI to enable improved understanding of the tumor microe...
Back to Newsroom